All In Biotech

Drug Trial Radar · NCT04404569

Continued Treatment for Participants Enrolled in Studies of BXQ-350

An Open-Label, Multi-Center, Rollover Study to Provide Continued Treatment Access for Participants Enrolled in Studies of BXQ-350

Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

5

Actual

Start

Jun 8, 2020

Primary completion

Sep 23, 2024

Study completion Sep 23, 2024

Sponsor

Lead sponsor
Bexion Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
CTI Clinical Trial and Consulting Services
First posted
May 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study. The additional treatment is optional and voluntary.

Conditions

  • Neoplasms

Interventions

  • BXQ-350Drug

    BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion in 28-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with clinical benefitTime frame: Day 1 up to approximately 5 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky

  • University of Cincinnati Barrett Center

    Cincinnati, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.